1. MAPK/ERK Pathway Autophagy Metabolic Enzyme/Protease Anti-infection
  2. MAP3K Autophagy Endogenous Metabolite HIV
  3. Oleanolic acid

Oleanolic acid  (Synonyms: Oleanic acid; Caryophyllin)

Cat. No.: HY-N0156 Purity: 98.0%
Handling Instructions Technical Support

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

For research use only. We do not sell to patients.

CAS No. : 508-02-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 21 publication(s) in Google Scholar

Other Forms of Oleanolic acid:

Top Publications Citing Use of Products

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Fourteen candidates were selected from 1900 FDA-approved and 30 of our own SE series compounds in primary screening for the SHP099 IC50 assay, and Oleanolic acid exhibited the best effect.

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Protein thermal stability analysis was performed to examine the effect of Oleanolic acid (0-100 μmol/L) on SHP2-E76K.

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Naive T cells from mice were treated with 30 μmol/L Oleanolic acid for different hours or various concentrations for 1 h. Protein levels were assessed by Western blot.

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Naive T cells from mice were treated with Oleanolic acid, followed by stimulation of IL-6 (25 ng/mL) for 30 min. Protein levels were assessed by Western blot (n = 3).

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Lymph node-derived T cells were treated or not with 30 μmol/L Oleanolic acid for 6 h, and the T cells were then treated with 25 ng/mL of IL-6 for 30 min. After incubation, the total protein was immunoprecipitated with an Ab against STAT3. The immunoprecipitants were assessed by Western blotting.

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Lymph node-derived T cells were treated with or without 30 μmol/L Oleanolic acid for 6 h, and the T cells were then treated with 25 ng/mL of IL-6 for 30 min. After treatment, the cells were analyzed by immunofluorescence. The results shown are representative of three independent experiments. Scale bar, 10 μm.

    Oleanolic acid purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Jun;14(6):2598-2612.

    Oleanolic acid ameliorated TNBS-induced experimental colitis in mice. Mice were challenged with TNBS on Day 0, and oral administration of Oleanolic acid was carried out from Days 0–4. After sacrifice on Day 4, colon damage was evaluated by colon length (n = 6).

    View All MAP3K Isoform Specific Products:

    View All Endogenous Metabolite Isoform Specific Products:

    View All HIV Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

    IC50 & Target

    ASK1

     

    Cellular Effect
    Cell Line Type Value Description References
    4T1 IC50
    514.1 μM
    Compound: 3; OA
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    518A2 EC50
    61.3 μM
    Compound: OA
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    518A2 EC50
    64.3 μM
    Compound: 1; OA
    Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    518A2 EC50
    64.3 μM
    Compound: OA
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    518A2 EC50
    > 30 μM
    Compound: 2
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    518A2 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    518A2 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    518A2 IC50
    > 60 μM
    Compound: OA
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    8505C EC50
    > 30 μM
    Compound: 2
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 28033541]
    8505C EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    8505C EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    8505C IC50
    > 60 μM
    Compound: OA
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 24361521]
    A-375 IC50
    328.8 μM
    Compound: 3; OA
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    A2780 EC50
    14 μM
    Compound: 1; OA
    Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    A2780 EC50
    14 μM
    Compound: 2
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    A2780 EC50
    14 μM
    Compound: OA
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    A2780 EC50
    58.2 μM
    Compound: OA
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    A2780 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    A2780 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    A2780 IC50
    14 μM
    Compound: OA
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    A2780 IC50
    8 μg/mL
    Compound: oleanolic acid
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    [PMID: 15217279]
    A2780 IC50
    >= 20 μg/mL
    Compound: 10
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    [PMID: 12662105]
    A549 EC50
    64.1 μM
    Compound: OA
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    A549 EC50
    72.3 μM
    Compound: 1; OA
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    A549 EC50
    72.3 μM
    Compound: OA
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    A549 EC50
    > 30 μM
    Compound: 2
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    A549 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    A549 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    A549 GI50
    > 100 μM
    Compound: 27
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 32345458]
    A549 IC50
    0.39 μM
    Compound: 1, OA
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 23434227]
    A549 IC50
    16.29 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    10.1039/C6MD00061D
    A549 IC50
    19.94 μM
    Compound: OA
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    A549 IC50
    209 μM
    Compound: 10
    Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 15730243]
    A549 IC50
    27 μM
    Compound: 4
    Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
    Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
    [PMID: 19200744]
    A549 IC50
    41.65 μM
    Compound: 1; OA
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    A549 IC50
    6.4 μM
    Compound: OA
    Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
    [PMID: 31718182]
    A549 IC50
    64.26 μM
    Compound: 3; OA
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    A549 IC50
    72.3 μM
    Compound: OA
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    A549 IC50
    81.4 μM
    Compound: OA
    Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay
    [PMID: 24422538]
    A549 IC50
    96.2 μM
    Compound: 10
    Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
    Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
    [PMID: 15730243]
    A549 IC50
    > 100 μM
    Compound: 1, oleanolic acid
    Cytotoxicity against human A549 cells after 1 hr by MTT assay
    Cytotoxicity against human A549 cells after 1 hr by MTT assay
    [PMID: 18343122]
    A549 IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    [PMID: 26343825]
    A549 IC50
    > 200 μM
    Compound: 4
    Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
    Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
    [PMID: 19200744]
    A549/TR IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    B16 IC50
    4.8 μM
    Compound: 18
    Growth inhibition of mouse B16 2F2 cells after 3 days
    Growth inhibition of mouse B16 2F2 cells after 3 days
    [PMID: 12027734]
    B16-F10 IC50
    106.4 μM
    Compound: 1, OA, Oleanolic acid
    Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
    [PMID: 24480359]
    B16-F10 IC50
    106.4 μM
    Compound: I, Oleanolic acid
    Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
    Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
    [PMID: 29471121]
    B16-F10 IC50
    106.4 μM
    Compound: I; OA; Oleanolic and
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27128174]
    B16-F10 IC50
    106.4 μM
    Compound: OA
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 36542806]
    B16-F10 IC50
    388.3 μM
    Compound: 3; OA
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    BGC-823 IC50
    2.59 μM
    Compound: 1, OA
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    [PMID: 23434227]
    BGC-823 IC50
    23.74 μM
    Compound: 1
    Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    10.1039/C6MD00061D
    BMDC IC50
    > 50 μM
    Compound: 22
    Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
    Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
    [PMID: 23484668]
    BMDC IC50
    > 50 μM
    Compound: 22
    Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
    Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
    [PMID: 23484668]
    BMDC IC50
    > 50 μM
    Compound: 22
    Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
    Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
    [PMID: 23484668]
    Bel-7402 IC50
    59.94 μM
    Compound: 1; OA
    Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    Bel7402/5-FU IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    CAPAN-1 IC50
    50.1 μM
    Compound: OA
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    CHO EC50
    2.25 μM
    Compound: 2
    Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
    Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
    [PMID: 19911773]
    COLO 205 IC50
    > 10 μM
    Compound: 6
    Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
    [PMID: 30199257]
    COLO 320 IC50
    > 10 μM
    Compound: 6
    Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay
    Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay
    [PMID: 30199257]
    DLD-1 IC50
    > 100 μM
    Compound: 4
    Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
    Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
    [PMID: 19200744]
    DLD-1 IC50
    > 200 μM
    Compound: 4
    Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
    Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
    [PMID: 19200744]
    DU-145 CC50
    65.6 μM
    Compound: 10
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    Cytotoxic activity in human DU145 cells by sulforhodamine B assay
    [PMID: 29120172]
    DU-145 IC50
    124 μM
    Compound: 10
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    Antiproliferative activity in human DU145 cells by sulforhodamine B assay
    [PMID: 29120172]
    FaDu EC50
    66.7 μM
    Compound: OA
    Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    FaDu EC50
    75.4 μM
    Compound: 1; OA
    Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    FaDu EC50
    75.4 μM
    Compound: OA
    Cytotoxicity against human FADU cells after 96 hrs by SRB assay
    Cytotoxicity against human FADU cells after 96 hrs by SRB assay
    [PMID: 26750249]
    FaDu EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    H9 EC50
    1.7 μg/mL
    Compound: 1
    Antiviral activity against HIV-1(IIIB) infected H9 cell lines.
    Antiviral activity against HIV-1(IIIB) infected H9 cell lines.
    [PMID: 11720855]
    H9 EC50
    1.7 μg/mL
    Compound: 1
    Cytotoxicity against mock-infected human H9 cells after 4 days
    Cytotoxicity against mock-infected human H9 cells after 4 days
    [PMID: 9748372]
    H9 EC50
    3.7 μM
    Compound: 3
    Cytotoxicity against mock-infected human H9 cells
    Cytotoxicity against mock-infected human H9 cells
    [PMID: 11141100]
    H9 IC50
    21.8 μg/mL
    Compound: 1
    Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.
    Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.
    [PMID: 11720855]
    H9 IC50
    21.8 μg/mL
    Compound: 1
    Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
    Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
    [PMID: 9748372]
    H9 IC50
    47.8 μM
    Compound: 3
    Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
    Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
    [PMID: 11141100]
    HCT-116 GI50
    > 100 μM
    Compound: 27
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 32345458]
    HCT-116 IC50
    32.4 μM
    Compound: OA
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    HCT-116 IC50
    4.8 μM
    Compound: Oleanolic acid
    Cytotoxicity against human HCT116 cells by MTT assay
    Cytotoxicity against human HCT116 cells by MTT assay
    [PMID: 20951582]
    HCT-116 IC50
    > 150 μM
    Compound: OA
    Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay
    Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay
    [PMID: 24422538]
    HEK293 CC50
    > 500 μM
    Compound: 10
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    Cytotoxic activity in HEK293 cells by sulforhodamine B assay
    [PMID: 29120172]
    HEK293 IC50
    329 μM
    Compound: 9
    Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay
    Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay
    [PMID: 26473275]
    HEK293 IC50
    > 500 μM
    Compound: 10
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    Antiproliferative activity in HEK293 cells by sulforhodamine B assay
    [PMID: 29120172]
    HEL EC50
    > 1 μM
    Compound: OA
    Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 33569941]
    HEp-2 CC50
    > 500 μM
    Compound: 10
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
    [PMID: 29120172]
    HEp-2 IC50
    > 500 μM
    Compound: 10
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
    [PMID: 29120172]
    HL-60 IC50
    14.75 μM
    Compound: 1; OA
    Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    HL-60 IC50
    16.17 μM
    Compound: OA
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    HL-60 IC50
    36.4 μM
    Compound: OA
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    [PMID: 34352711]
    HL-60 IC50
    54.56 μM
    Compound: 1, OA
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    10.1039/C2MD20051A
    HL-60 IC50
    77.48 μM
    Compound: Oleanolic acid
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    [PMID: 20951582]
    HL-60 IC50
    > 30 μM
    Compound: 1; OA
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 29133061]
    HL-60 IC50
    > 50 μg/mL
    Compound: oleanolic acid
    Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay
    [PMID: 10514313]
    HL60/ADR IC50
    28.75 μM
    Compound: 1; OA
    Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    HSC-T6 EC50
    59.6 nM
    Compound: 139
    Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
    [PMID: 29353722]
    HT-29 EC50
    38.8 μM
    Compound: 1; OA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    HT-29 EC50
    38.8 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    HT-29 EC50
    44.9 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    HT-29 EC50
    > 10 μM
    Compound: 8
    Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
    Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay
    [PMID: 33248849]
    HT-29 EC50
    > 30 μM
    Compound: 2
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    HT-29 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    HT-29 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    HT-29 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    HT-29 IC50
    38.8 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    HT-29 IC50
    429.9 μM
    Compound: I, Oleanolic acid
    Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
    Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
    [PMID: 29471121]
    HT-29 IC50
    429.9 μM
    Compound: I; OA; Oleanolic and
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27128174]
    HT-29 IC50
    429.9 μM
    Compound: OA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 36542806]
    HT-29 IC50
    > 10 μM
    Compound: 8
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    HT-29 IC50
    > 10 μM
    Compound: 8
    Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
    Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
    [PMID: 30057155]
    HT-29 IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    [PMID: 24487188]
    HT-29 IC50
    > 30 μM
    Compound: 1; OA
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 29133061]
    HeLa CC50
    > 500 μM
    Compound: 10
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    Cytotoxic activity in human HeLa cells by sulforhodamine B assay
    [PMID: 29120172]
    HeLa IC50
    204.5 μM
    Compound: 10
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    Antiproliferative activity in human HeLa cells by sulforhodamine B assay
    [PMID: 29120172]
    HeLa IC50
    31.38 μM
    Compound: OA
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    HeLa IC50
    4 μM
    Compound: 1
    Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs
    Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs
    [PMID: 21561086]
    HeLa IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 24487188]
    HeLa IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
    [PMID: 26343825]
    HeLa IC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    [PMID: 38039788]
    HepG2 IC50
    14.72 μM
    Compound: OA
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    HepG2 IC50
    15.9 μM
    Compound: 1
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    10.1039/C6MD00061D
    HepG2 IC50
    165 μM
    Compound: 10
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    HepG2 IC50
    211.8 μM
    Compound: I, Oleanolic acid
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
    [PMID: 29471121]
    HepG2 IC50
    211.8 μM
    Compound: I; OA; Oleanolic and
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
    [PMID: 27128174]
    HepG2 IC50
    211.8 μM
    Compound: OA
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 36542806]
    HepG2 IC50
    51.4 μM
    Compound: OA
    Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay
    Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay
    [PMID: 24422538]
    HepG2 IC50
    > 10 μM
    Compound: 16
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    HepG2 IC50
    > 100 μM
    Compound: 11
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    HepG2 IC50
    > 200 μM
    Compound: OA
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    [PMID: 37742398]
    HepG2 IC50
    > 280 μM
    Compound: 4b
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    [PMID: 25442310]
    HepG2 IC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    [PMID: 38039788]
    HepG2 2.2.15 CC50
    731.2 μM
    Compound: D1; OA
    Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
    Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
    [PMID: 29627260]
    J774 IC50
    130.5 μM
    Compound: 8
    Cytotoxicity against mouse J774 cells by alamar blue assay
    Cytotoxicity against mouse J774 cells by alamar blue assay
    [PMID: 17637068]
    J774.A1 IC50
    35.2 μM
    Compound: 1, Oleanolic acid
    Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
    Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
    [PMID: 25113933]
    J774.A1 IC50
    87.22 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control
    Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control
    [PMID: 25113933]
    Jurkat EC50
    > 1 μM
    Compound: OA
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 33569941]
    K562 EC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 33569941]
    K562 IC50
    58.13 μM
    Compound: 1, OA
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    10.1039/C2MD20051A
    K562 IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    [PMID: 34352711]
    K562 IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    K562/Adr IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    KB CC50
    > 500 μM
    Compound: 10
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    Cytotoxic activity in human KB cells by sulforhodamine B assay
    [PMID: 29120172]
    KB IC50
    > 10 μM
    Compound: OA
    Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
    [PMID: 31718182]
    KB IC50
    > 100 μM
    Compound: 11
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    KB IC50
    > 280 μM
    Compound: 4b
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    [PMID: 25442310]
    KB IC50
    > 500 μM
    Compound: 10
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    Antiproliferative activity in human KB cells by sulforhodamine B assay
    [PMID: 29120172]
    L02 IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    L02 IC50
    > 200 μM
    Compound: OA
    Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    [PMID: 37742398]
    L5178Y IC50
    > 10 μM
    Compound: 6
    Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay
    [PMID: 30199257]
    L5178Y IC50
    > 10 μM
    Compound: 6
    Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay
    Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay
    [PMID: 30199257]
    LN-229 IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    Lu1 IC50
    > 100 μM
    Compound: 11
    Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    M14 IC50
    82 μM
    Compound: 5
    Cytotoxicity against human M14 cells after 48 hrs by MTT assay
    Cytotoxicity against human M14 cells after 48 hrs by MTT assay
    [PMID: 21954959]
    MCF-12A IC50
    > 50 μM
    Compound: 1; OA
    Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    MCF7 CC50
    > 500 μM
    Compound: 10
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
    [PMID: 29120172]
    MCF7 EC50
    49.1 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    MCF7 EC50
    80 μM
    Compound: 1; OA
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    MCF7 EC50
    80 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    MCF7 EC50
    > 30 μM
    Compound: 2
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    MCF7 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    MCF7 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    MCF7 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    MCF7 GI50
    10.3 μM
    Compound: 1; OA
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 28754470]
    MCF7 GI50
    > 100 μM
    Compound: 27
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32345458]
    MCF7 IC50
    12.6 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    10.1039/C6MD00061D
    MCF7 IC50
    12.7 μM
    Compound: 1; OA
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    MCF7 IC50
    35.4 μM
    Compound: 1, OA
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 23434227]
    MCF7 IC50
    4.23 nM
    Compound: 52; OA
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 37847948]
    MCF7 IC50
    > 10 μM
    Compound: 16
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    MCF7 IC50
    > 10 μM
    Compound: OA
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
    [PMID: 31718182]
    MCF7 IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 24487188]
    MCF7 IC50
    > 100 μM
    Compound: 11
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    MCF7 IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
    [PMID: 26343825]
    MCF7 IC50
    > 150 μM
    Compound: 9
    Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 19618898]
    MCF7 IC50
    > 150 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay
    Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay
    [PMID: 24422538]
    MCF7 IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    MCF7 IC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    [PMID: 38039788]
    MCF7 IC50
    > 500 μM
    Compound: 10
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
    [PMID: 29120172]
    MCF7 IC50
    > 60 μM
    Compound: OA
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    MDA-MB-231 CC50
    106 μM
    Compound: 10
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
    [PMID: 29120172]
    MDA-MB-231 GI50
    17.6 μM
    Compound: 1; OA
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 28754470]
    MDA-MB-231 IC50
    134 μM
    Compound: 10
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
    [PMID: 29120172]
    MDA-MB-231 IC50
    512.4 μM
    Compound: 3; OA
    Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    MDA-MB-231 IC50
    67.87 μM
    Compound: 1, OA
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    10.1039/C2MD20051A
    MDA-MB-231 IC50
    > 10 μM
    Compound: 8
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    MDA-MB-231 IC50
    > 10 μM
    Compound: OA
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
    [PMID: 31718182]
    MDA-MB-231 IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    [PMID: 24487188]
    MDA-MB-231 IC50
    > 30 μM
    Compound: OA
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
    [PMID: 38039788]
    MDA-MB-231 IC50
    > 50 μM
    Compound: 1; OA
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    MDA-MB-435 IC50
    > 10 μM
    Compound: 8
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    MDA-MB-453 IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay
    [PMID: 24487188]
    MDA-MB-468 IC50
    38.1 μM
    Compound: 1; OA
    Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    MDCK CC50
    23.1 μM
    Compound: OA
    Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay
    Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay
    [PMID: 27153348]
    MDCK CC50
    > 100 μM
    Compound: OA
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay
    [PMID: 31425909]
    MDCK CC50
    > 100 μM
    Compound: OA
    Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay
    Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay
    [PMID: 34795865]
    MDCK CC50
    > 100 μM
    Compound: OA
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by celltiter-glo assay
    Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by celltiter-glo assay
    [PMID: 37354741]
    MDCK IC50
    > 50 μM
    Compound: OA
    Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by luciferase based plaque reduction assay
    Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by luciferase based plaque reduction assay
    [PMID: 27153348]
    ME-180 IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human ME180 cells after 48 hrs by MTT assay
    Cytotoxicity against human ME180 cells after 48 hrs by MTT assay
    [PMID: 24487188]
    MGC-803 IC50
    > 200 μM
    Compound: OA
    Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    [PMID: 37742398]
    MRC5 IC50
    > 10 μM
    Compound: 6
    Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay
    [PMID: 30199257]
    Macrophage CC50
    29.69 μM
    Compound: Oleanolic acid
    Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay
    Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay
    [PMID: 36701870]
    Macrophage IC50
    18.64 μM
    Compound: Oleanolic acid
    Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay
    Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay
    [PMID: 36701870]
    Macrophage IC50
    > 40 μM
    Compound: 3
    Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method
    Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method
    [PMID: 23837912]
    NCI-H1975 IC50
    > 10 μM
    Compound: OA
    Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
    Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
    [PMID: 31718182]
    NCI-H1975 IC50
    > 10 μM
    Compound: OA
    Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
    Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
    [PMID: 31718182]
    NCI-H460 IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    NCI-N87 IC50
    > 10 μM
    Compound: 16
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    NCI/ADR-RES IC50
    > 200 μM
    Compound: 1; OA
    Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    NIH3T3 EC50
    57.9 μM
    Compound: OA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
    [PMID: 29529499]
    NIH3T3 EC50
    76.4 μM
    Compound: 1; OA
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    NIH3T3 EC50
    76.4 μM
    Compound: OA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    NIH3T3 EC50
    > 30 μM
    Compound: 2
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    NIH3T3 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
    [PMID: 30278332]
    NIH3T3 EC50
    > 30 μM
    Compound: OA
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    NIH3T3 IC50
    76.4 μM
    Compound: OA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 24361521]
    NIH3T3 IC50
    > 10 μM
    Compound: 6
    Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
    [PMID: 30199257]
    Neutrophil IC50
    0.75 μM
    Compound: 15
    Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins
    Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins
    [PMID: 21417387]
    Neutrophil IC50
    1.37 μM
    Compound: 15
    Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils
    Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils
    [PMID: 21417387]
    OVCAR-3 IC50
    > 10 μM
    Compound: 8
    Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    PANC-1 IC50
    362.8 μM
    Compound: 3; OA
    Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    PC-12 EC50
    8.55 μM
    Compound: 1
    Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells
    Neuroprotective activity against CoCl2-induced neuronal injury in rat PC12 cells
    [PMID: 31924497]
    PC-3 IC50
    211 μM
    Compound: 8
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    [PMID: 16441066]
    PC-3 IC50
    6.51 μM
    Compound: 1, OA
    Cytotoxicity against human PC3 cells by MTT assay
    Cytotoxicity against human PC3 cells by MTT assay
    [PMID: 23434227]
    PC-3 IC50
    72.74 μM
    Compound: 1
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    10.1039/C6MD00061D
    PC-3 IC50
    > 100 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    [PMID: 24487188]
    PC-3 IC50
    > 30 μM
    Compound: 1; OA
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 29133061]
    RAW264.7 CC50
    145.47 μM
    Compound: Oleanolic acid
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36701870]
    RAW264.7 IC50
    41.7 μM
    Compound: 1, Oleanolic acid
    Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
    Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction
    [PMID: 25113933]
    RAW264.7 IC50
    89.12 μM
    Compound: 1, Oleanolic acid
    Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control
    Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control
    [PMID: 25113933]
    RAW264.7 IC50
    96.63 μM
    Compound: Oleanolic acid
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay
    [PMID: 36701870]
    Raji IC50
    389 molar ratio
    Compound: oleanolic acid
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation
    [PMID: 18387711]
    Raji IC50
    449 nM
    Compound: Oleanolic acid
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs
    [PMID: 21620532]
    Raji IC50
    449 molar ratio
    Compound: Oleanolic acid
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs
    Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs
    [PMID: 20153563]
    SK-MEL IC50
    112 μM
    Compound: 1
    Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL
    Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL
    [PMID: 10450948]
    SK-MEL IC50
    112 μM
    Compound: 1
    Cytotoxicity against human malignant melanoma cell line SK-MEL
    Cytotoxicity against human malignant melanoma cell line SK-MEL
    [PMID: 11425522]
    Sf21 IC50
    > 40 μM
    Compound: 10
    Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
    Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
    [PMID: 31774676]
    Sf9 IC50
    > 20 μM
    Compound: OA
    Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
    Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
    [PMID: 31718182]
    Sf9 IC50
    > 20 μM
    Compound: OA
    Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
    Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
    [PMID: 31718182]
    Sf9 IC50
    > 20 μM
    Compound: OA
    Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
    Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
    [PMID: 31718182]
    SiHa CC50
    108.7 μM
    Compound: 10
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    Cytotoxic activity in human SiHa cells by sulforhodamine B assay
    [PMID: 29120172]
    SiHa IC50
    110.2 μM
    Compound: 10
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    Antiproliferative activity in human SiHa cells by sulforhodamine B assay
    [PMID: 29120172]
    T-24 IC50
    66.86 μM
    Compound: OA
    Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
    [PMID: 37742398]
    T47D IC50
    36.22 μM
    Compound: 1; OA
    Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    U-87MG ATCC IC50
    18.52 μM
    Compound: OA
    Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
    [PMID: 23992864]
    Vero CC50
    > 500 μM
    Compound: 10
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
    [PMID: 29120172]
    Vero IC50
    > 250 μM
    Compound: 8
    Cytotoxicity against african green monkey Vero cells
    Cytotoxicity against african green monkey Vero cells
    [PMID: 16441066]
    Vero IC50
    > 500 μM
    Compound: 10
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
    [PMID: 29120172]
    WI-38 IC50
    14.5 μM
    Compound: 10
    Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    WI-38 VA13 IC50
    123 μM
    Compound: 10
    Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    Z-138 IC50
    > 100 μM
    Compound: OA
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    [PMID: 34352711]
    In Vitro

    Oleanolic acid (OA) suppresses the proliferation of lung cancer cells in both dose- and time-dependent manners, along with an increase in miR-122 abundance. CCNG1 and MEF2D, two putative miR-122 targets, are found to be downregulated by OA treatment [1]. OA induces autophagy in normal tissue-derived cells without cytotoxicity. OA-induced autophagy is shown to decrease the proliferation of KRAS-transformed normal cells and to impair their invasion and anchorage-independent growth[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Mouse model experiments also demonstrat that OA suppresses the growth of KRAS-transformed breast epithelial cell MCF10A-derived tumor xenograft by inducing autophagy [2]. Activation of MAPK pathways, including p-38 MAPK, JNK and ERK, is triggered by OA in both a dose and time-dependent fashion in all the tested cancer cells. OA induces p38 MAPK activation promoted mitochondrial translocation of Bax and Bim, and inhibits Bcl-2 function by enhancing their phosphorylation. OA can induce reactive oxygen species (ROS)-dependent ASK1 activation, and this event is indispensable for p38 MAPK-dependent apoptosis in cancer cells[3].It is also proved that p38 MAPK knockdown A549 tumors are resistant to the growth-inhibitory effect of OA[3]. In OA-treated EAM mice the number of Treg cells and the production of IL-10 and IL-35 are markedly increased, while proinflammatory and profibrotic cytokines are significantly reduced[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    456.70

    Formula

    C30H48O3

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@]([C@@]1([H])[C@]2(CC[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMF : 45.45 mg/mL (99.52 mM; ultrasonic and warming and heat to 60°C)

    DMSO : 5 mg/mL (10.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1896 mL 10.9481 mL 21.8962 mL
    5 mM 0.4379 mL 2.1896 mL 4.3792 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 0.5 mg/mL (1.09 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 0.5 mg/mL (1.09 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 2 mg/mL (4.38 mM); Suspended solution; Need ultrasonic

    • Protocol 2

      Add each solvent one by one:  10% Tween-80 in Saline

      Solubility: 5 mg/mL (10.95 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.0%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / DMF 1 mM 2.1896 mL 10.9481 mL 21.8962 mL 54.7405 mL
    5 mM 0.4379 mL 2.1896 mL 4.3792 mL 10.9481 mL
    10 mM 0.2190 mL 1.0948 mL 2.1896 mL 5.4741 mL
    DMF 15 mM 0.1460 mL 0.7299 mL 1.4597 mL 3.6494 mL
    20 mM 0.1095 mL 0.5474 mL 1.0948 mL 2.7370 mL
    25 mM 0.0876 mL 0.4379 mL 0.8758 mL 2.1896 mL
    30 mM 0.0730 mL 0.3649 mL 0.7299 mL 1.8247 mL
    40 mM 0.0547 mL 0.2737 mL 0.5474 mL 1.3685 mL
    50 mM 0.0438 mL 0.2190 mL 0.4379 mL 1.0948 mL
    60 mM 0.0365 mL 0.1825 mL 0.3649 mL 0.9123 mL
    80 mM 0.0274 mL 0.1369 mL 0.2737 mL 0.6843 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Oleanolic acid
    Cat. No.:
    HY-N0156
    Quantity:
    MCE Japan Authorized Agent: